How Will the Market React to CASI Pharmaceuticals Inc (CASI) Stock Getting a Bullish Rating

Overall market sentiment has been high on CASI Pharmaceuticals Inc (CASI) stock lately. CASI receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

CASI Pharmaceuticals Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CASI!

See Full CASI Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With CASI Stock Today?

CASI Pharmaceuticals Inc (CASI) stock is trading at $3.18 as of 10:37 AM on Tuesday, Oct 10, a rise of $0.21, or 7.07% from the previous closing price of $2.97. The stock has traded between $3.04 and $3.18 so far today. Volume today is low. So far 8,423 shares have traded compared to average volume of 16,058 shares.

More About CASI Pharmaceuticals Inc

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing innovative therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA. The company primarily operates in the United States, Canada, China and other parts of the world. Click Here to get the full Stock Report for CASI Pharmaceuticals Inc stock.